Table 7.
Univariate analysis of prognostic factors in patients with gastric cancer [cases (%)]
| Factors | Cases | 1-year survival rate | χ2 | P | 3-year survival rate | χ2 | P | |
|---|---|---|---|---|---|---|---|---|
| Gender | Male | 83 | 73 (87.95) | 1.354 | 0.245 | 55 (66.27) | 0.759 | 0.384 |
| Female | 69 | 56 (81.16) | 41 (59.42) | |||||
| Age | < 60 years old | 51 | 48 (94.12) | 5.113 | 0.024 | 40 (78.43) | 7.695 | 0.006 |
| ≥ 60 years old | 101 | 81 (80.20) | 56 (55.44) | |||||
| Tumor location | Upper 1/3 | 77 | 68 (88.31) | 1.441 | 0.230 | 48 (62.34) | 0.045 | 0.832 |
| Lower 1/3 | 75 | 61 (81.33) | 48 (64.00) | |||||
| Tumor diameter | < 5 cm | 112 | 105 (93.75) | 26.143 | < 0.001 | 85 (75.89) | 29.664 | < 0.001 |
| ≥ 5 cm | 40 | 24 (60.00) | 11 (27.50) | |||||
| TNM stage | I ~ II | 102 | 98 (96.08) | 30.343 | < 0.001 | 70 (68.63) | 3.987 | 0.046 |
| III ~ IV | 50 | 31 (62.00) | 26 (52.00) | |||||
| Degree of differentiation | Low differentiation | 69 | 58 (94.06) | 0.065 | 0.799 | 48 (62.34) | 2.229 | 0.135 |
| Medium and high differentiation | 83 | 71 (85.54) | 48 (64.00) | |||||
| Lymph node metastasis | N0 ~ N1 | 95 | 90 (94.74) | 19.211 | < 0.001 | 69 (72.63) | 9.771 | 0.002 |
| N2 ~ N3 | 57 | 39 (68.42) | 27 (47.37) | |||||
| Chemotherapy regimen | Oxaliplatin | 76 | 69 (90.79) | 4.150 | 0.042 | 41 (53.95) | 5.542 | 0.019 |
| Capecitabine + oxaliplatin | 76 | 60 (78.95) | 55 (72.37) | |||||
| FOXP1 | Low expression | 66 | 50 (75.76) | 7.540 | 0.006 | 36 (53.03) | 5.142 | 0.023 |
| High expression | 86 | 79 (91.86) | 61 (70.93) | |||||
| GGT | < 387.2 (U/L) | 58 | 55 (94.82) | 7.244 | 0.007 | 47 (81.03) | 12.881 | < 0.001 |
| ≥ 387.2 (U/L) | 94 | 74 (78.72) | 49 (52.13) | |||||